ArticleMedical journal of the Islamic Republic of Iran2024
The Impact of Empagliflozin on Inflammatory Markers in Adults with Type 2 Diabetes: A Retrospective Cohort.
Article in Medical journal of the Islamic Republic of Iran, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation plays a significant role in the development and progression of type 2 diabetes (T2D). Empagliflozin, an SGLT2 inhibitor, has shown some anti-inflammatory effects in patients with T2D. This study aimed to evaluate the impact of empagliflozin on some inflammatory markers in T2D. Methods: This retrospective single-arm cohort study included 40 patients with T2D who were treated with empagliflozin. Inflammatory markers such as serum level of erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and serum albumin were evaluated at baseline and 12 weeks after empagliflozin treatment. Statistical analysis used paired samples t test, and the statistically significant level was considered Results: After 12 weeks, a significant reduction was found in ESR (17.75 ± 15.7 mm/hr to 14.72 ± 10.93 mm/hr; Conclusion: Empagliflozin showed anti-inflammatory effects by reducing ESR and PLR and increasing serum albumin and lymphocyte count in adults with T2D. Monitoring inflammatory markers can serve as an indicator of treatment effectiveness in T2D patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.